Ashwagandha for Sleep Quality in Stressed Adults
Trials show ashwagandha eases stress and sleep, but cortisol is murky.

Tired but wired. That's the state a lot of stressed adults live in most nights: exhausted enough to want sleep, keyed up enough that it won't come. Chronic stress and poor sleep run on the same axis, the hypothalamic-pituitary-adrenal (HPA) system, and once it's dysregulated, each side of the equation feeds the other.
The loop, in plain terms, works like this. Sustained HPA activation keeps cortisol elevated well past the point where it should have tapered off, and that elevated cortisol works directly against the conditions the brain needs to fall asleep and stay asleep. So the person lies there, cortisol still circulating, sleep either delayed or shallow and broken. The next day, having slept badly, the HPA axis doesn't reset itself. Instead it fires harder, and cortisol comes back up even higher than the day before. One bad night doesn't just cost a day of tiredness. It raises the stress load going into the next night, which raises the odds of another bad night, and the loop tightens.
The damage doesn't stop at feeling foggy or irritable. Chronic stress, HPA dysregulation, and the neuroinflammation that follows from it form a documented route to actual cognitive impairment, not the ordinary tiredness people wave off with coffee. And the reach extends past the brain: sustained HPA dysfunction alters heart rate, body temperature regulation, and metabolic function, and this raises the cycle's cost in the body as much as in mood or memory. None of this is a niche complaint, either. Stress-linked insomnia is one of the most common sleep complaints reported worldwide. The cycle described here is closer to the default condition of modern adult life than an edge case.
Ashwagandha's intervention at the biological root of the cycle
Ashwagandha's reputation as a "calming herb" undersells what it actually does. It isn't one sedative compound smoothing things over. It works through at least three separate mechanisms, each aimed at a different link in the stress-sleep chain described above.
The first is upstream, at the HPA axis itself. Withanolides, the root's main steroidal lactones, modulate HPA activity directly, which brings cortisol down and stabilizes the stress response before it has the chance to disrupt sleep or grind down cognitive function later. The second mechanism runs through the brain's own relaxation chemistry: compounds in ashwagandha boost GABA and serotonin receptor activity, the same signaling pathways the brain uses on its own to wind down at night.
The third mechanism changes how the sleep benefit should be understood. A non-withanolide compound called triethylene glycol, or TEG, appears in water extracts of the plant and promotes sleep in a dose-dependent way. The notable part is what TEG does not do: it leaves NREM EEG power density unchanged, so the sleep it produces looks physiologically normal on a brain-wave level. Benzodiazepines, by contrast, flatten that EEG power and distort the underlying architecture of sleep even while knocking a person out. That's not a small distinction.
Ashwagandha appears to support brain-derived neurotrophic factor, or BDNF, a protein tied to neuroplasticity that chronic stress is known to suppress. Restoring it has consequences that appear later, in the cognition section below. For now, the more immediate takeaway is a quality-control one: because TEG and other non-withanolide compounds carry their own sleep-promoting activity, judging a product purely by its withanolide percentage misses part of what actually makes it work. This TEG finding is mechanistically significant, indicating that the sleep benefit appears to be qualitatively different from pharmacological sedation, preserving rather than suppressing normal sleep stages.
What clinical trials in stressed adults show
Mechanism is one thing. Whether it plays out in actual stressed adults, measured over weeks rather than in a petri dish, is the harder question, and the trial record answers it with a qualified yes.
By day 28, and again at 56 and 84, Zenroot™ (ZEN, 125 mg standardized to withanolides) produced significant improvements in Perceived Stress Scale (PSS), Beck Anxiety Inventory (BAI), and Pittsburgh Sleep Quality Index (PSQI) scores compared to placebo. Objective measures moved too: skin conductance response and heart rate variability metrics (RMSSD and SDNN) improved alongside the self-reported scores.
In the insomnia subgroup, sleep quality improved, sleep onset came faster, morning alertness rose, and anxiety symptoms eased, measured by actigraphy and validated rating scales. A 2026 dose-response meta-analysis in Complementary Therapies in Medicine pooled several trials and found consistent gains across stress, anxiety, and depression scores. A larger cortisol meta-analysis in BJPsych Open confirmed statistically significant drops in cortisol along with improvement on the PSS and HAM-A scales, concluding that ashwagandha is safe and effective for reducing stress and anxiety in adults, though it found no significant gain in quality-of-life measures.
The cognitive angle has its own trial line. A 2026 Frontiers meta-analysis confirmed gains in memory, attention, processing speed, and executive function among adults generally, while a separate 2025 study by Rai and Mishra reported specific gains in immediate memory, working memory, attention, and processing speed among people with mild cognitive impairment. That's the eventual payoff of breaking the cycle described earlier, and it's picked back up in a later section.
A trial protocol published in the Journal of Clinical and Diagnostic Research sets up a head-to-head comparison between Bacopa monnieri (Brahmi ghana) and ashwagandha ghana on stress and sleep quality in stressed adults, tracked via PSS and PSQI at 15-day intervals over a multi-week period. Worth watching, not yet conclusive.
Threaded through all of this, though, is that Zenroot cortisol non-finding. It's a preview of a bigger question the field hasn't settled, and it deserves its own treatment. The National University of Natural Medicine Trial (NCT07151261, completed May 2026) is a phase II, randomized, placebo-controlled trial examining ashwagandha root extract sustained-release capsules (150 mg) specifically on disturbed sleep (including nighttime waking), using wearable device monitoring, with the trial running October 2025 to May 2026 and results not yet published in the open literature.
The key scientific tension: cortisol falls, but does the person feel better
The honest version of this story gets complicated here, in the place where a lot of supplement marketing quietly looks away. A 2025 systematic review and meta-analysis covering eight randomized controlled trials in a large adult sample found a statistically significant drop in cortisol levels, but no significant change in perceived stress as measured by the PSS. Cortisol went down. People didn't report feeling less stressed. The authors pointed to short treatment windows and narrow, non-representative samples as likely reasons for the gap, not evidence that the effect isn't real.
Then the Zenroot trial runs the pattern in reverse. Its subjects reported significant improvement on the PSS, feeling genuinely less stressed, yet cortisol showed no significant difference between the treatment and placebo groups. So one major study found a biomarker shift without felt relief, and another found felt relief without a biomarker shift. Read together, they say something specific: cortisol and perceived stress are not the same variable wearing two names. Cortisol isn't the sole engine behind how stressed someone feels, and lowering it doesn't guarantee the person will notice. But a null result on cortisol doesn't mean nothing happened, either. Two different mechanisms, two different outcome measures, and neither one is the whole picture on its own.
This should be read as an honest limitation in an immature evidence base rather than grounds to dismiss the compound. Cortisol assays are notoriously variable across time of day, sample type, and lab method, and perceived stress scales capture something psychological that a single blood or saliva measurement was never built to explain. Longer trials with broader populations would help sort out which pathway dominates and under what conditions.
Sleep is a different story. Across trials in insomnia-prone stressed adults, the sleep outcome appears repeatedly, and in the KSM-66 trial it was captured by actigraphy rather than relying on subjects' memory of how they slept. Of everything in the current literature, that's the signal that holds up best under scrutiny, and it's the one that carries directly into what happens the next day.
How better sleep translates into daytime cognitive performance
Restored sleep isn't the end goal so much as the mechanism by which everything else improves. A 2025 study examining ashwagandha extract across physiological, biochemical, and neurobiological measures found it protected against stress-induced damage to cognitive performance and neuroplasticity. The 2026 Frontiers meta-analysis backs this at the more granular level, confirming gains in immediate memory, working memory, attention, and processing speed specifically among people with mild cognitive impairment. And the KSM-66 insomnia trial captured something easy to overlook but functionally important: mental alertness on rising, the actual bridge between a good night's sleep and a productive morning.
The mechanistic story holds together end to end. HPA modulation keeps cortisol from grinding down the prefrontal cortex. GABAergic signaling supports deeper, more restorative sleep instead of the shallow, interrupted kind that leaves someone groggy at 7 a.m. BDNF preservation protects the neuroplasticity that memory and learning actually run on. Three separate mechanisms, one coherent outcome.
This is a specific kind of intervention, and the framing matters. Ashwagandha is not a stimulant stacked on top of an already stressed, sleep-deprived system, pushing output higher while the underlying damage accumulates. It works by lowering the load on that system in the first place, and the cognitive gains follow from the system getting room to recover rather than being pushed harder. That distinction runs against a common assumption in the cognitive performance conversation, the idea that energy and calm are a trade-off, that you sacrifice one for the other. Removing cortisol's drag on cognition does both at once: less felt stress and more mental output, from the same intervention.
Formulation and absorption determine whether any of this applies to a given product
None of the above matters if the product on the shelf doesn't deliver the compound in a form the body can use. A lot of "ashwagandha works" claims quietly fall apart here, because the question was never the plant's chemistry. It's whether a given extract gets that chemistry into the bloodstream at all.
A randomized, double-blind, crossover bioavailability study published in Current Therapeutic Research makes the point directly: withanolide glycosides matter for their quality, not just their quantity, and the strength of an ashwagandha extract lies in its withanolide profile rather than the raw total printed on the label. Benny Antony, PhD, joint managing director at Arjuna Natural, made that same point commenting on the study. Withanolide glycosides in particular tend to be poorly soluble, and that solubility problem can cap bioavailability and clinical effect no matter how high the stated dose runs.
The Zenroot formulation is the cleanest real-world demonstration of this. A smaller dose, better absorbed, beat larger doses built on cruder extraction. Milligrams on a label tell you almost nothing about what actually crosses into the blood.
Standardization method also determines the outcome. Research should be built on standardized water-alcoholic preparations with withanolide content verified by HPLC, following USP guidelines that define seven specific peaks for withanolide analysis, a more precise standard than a lot of earlier studies used. TEG's sleep-promoting activity turned up specifically in water extracts carrying low withanolide levels, a wrinkle recalled from the mechanism section. An extraction process chasing the highest possible withanolide count, typically an alcohol-heavy process, risks stripping out the very compound responsible for part of the sleep benefit. Chasing one number can quietly undercut the other.
For anyone actually shopping for a product, the practical checklist is short: standardized extracts with a disclosed withanolide profile, HPLC-verified content, and a delivery system built to address poor solubility, rather than the highest milligram figure on the front of the bottle. The Zenroot™ formulation demonstrated this practically: at a 125-mg dose, it showed higher bioavailability compared to two commercial products with higher withanolide concentrations at larger doses, so a smaller dose, better absorbed, outperformed larger doses with cruder extraction.
Safety considerations and populations for whom ashwagandha warrants caution
The safety record in healthy adults, at the doses and durations studied, is solid.
That said, a fuller picture requires acknowledging what's turned up on the liver side. A scoping review in Cureus, published in May 2026, mapped every peer-reviewed case of ashwagandha-associated liver injury on record through December 2025, and the cases document a real hepatotoxic risk, even if an uncommon one. Regulators haven't ignored it. Danish, Dutch, French, Belgian, and German authorities have either banned ashwagandha outright or raised formal concerns, and the UK's Food Standards Agency opened a consultation and has since published a summary of responses, though the full risk assessment is still pending. Germany's BfR went further in a 2024 communication, warning that ashwagandha supplements carry potential health risks and naming specific groups who should avoid them: children, pregnant women, breastfeeding mothers, and anyone with existing liver disease.
None of that erases the trial evidence for healthy adults managing ordinary chronic stress and poor sleep. It does mean the caution has a shape, aimed at particular populations rather than the supplement as a whole, and any responsible use of ashwagandha should respect that shape rather than treat it as a footnote. The Zenroot™ RCT (84 days [sourced]) reported no related adverse events and described the product as well tolerated, consistent with the broader trial record in healthy adults at controlled doses. A 2023 systematic review in Nutrients found no significant adverse effects reported across nine trials running 30 to.
Sources
- A New Ashwagandha Formulation (Zenroot™) Alleviates Stress and Anxiety Symptoms While Improving Mood and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Clinical Study - PubMed
- Effects of ashwagandha (Withania somnifera) on mental health in adults: A systematic review and dose–response meta-analysis of randomized controlled trials - ScienceDirect
- Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis | PLOS One
- Ashwagandha (Withania somnifera) and Its Effects on Well-Being—A Review
- Journal of Clinical and Diagnostic Research. 2025 Jan, Vol-19(1): YK05-YK07 5
- A New Ashwagandha Formulation (Zenroot™) Alleviates Stress and Anxiety Symptoms While Improving Mood and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Clinical Study | Advances in Therapy | Springer Nature Link
- Ashwagandha might reduce cortisol, but not perceived stress - Study Summary
- Dual impact of Ashwagandha: Significant cortisol reduction but no effects on perceived stress - A systematic review and meta-analysis | Request PDF


